Madrigal Pharmaceuticals (MDGL) Stock Forecast & Price Target

Madrigal Pharmaceuticals is positioned favorably because Rezdiffra is the first approved MASH therapy, and early launch metrics plus physician feedback suggest strong demand, safety confidence, and meaningful room for penetration in a market with roughly 10-20M U.S. patients and only modest current treatment coverage. The company’s model now assumes 193k U.S. peak patients on Rezdiffra by 2036E and $8.9B in worldwide peak adjusted revenue, supported by a higher estimated long-term gross-to-net of 45% and expectations for continued adoption in F2/F3 disease. The Arrowhead deal strengthens the story further by adding ARO-PNPLA3 at $25M upfront with up to $975M in milestones and royalties, bringing human proof-of-concept, up to 46% liver fat reduction, and a precise combination opportunity that broadens Madrigal beyond a single-asset thesis.

Madrigal Pharmaceuticals is exposed to meaningful fundamental risk because Rezdiffra still faces unexpected safety issues, potential underperformance in MASH F4 patients, and an unfavorable regulatory backdrop that could reduce FDA and EMA approvals. The bearish case is also reinforced by a highly competitive MASH market, where new entrants may displace Rezdiffra in clinical practice, while the company’s own model assumes zero terminal value beyond 2033, highlighting dependence on a finite commercialization window. Although projected peak sales reach nearly $9.4B in 2033 for fibrotic MASH and about $1B in cirrhotic MASH, the need to fund operations at reasonable terms and the risk of delayed or equivocal Outcomes data could materially undermine that thesis.